ViGenCell Soars on Conditional Approval Hopes...DAEHWA Pharm Jumps[K-Bio Pulse]
[Song Young Doo, Edaily Repoter] ViGenCell Co., Ltd.
continued its rally after reporting successful Phase 2 results for its cell therapy candidate VT-EBV-N, with shares hitting the upper trading limit on the 8th.
Investors grew optimistic about the potential for conditional approval in Korea as early as the first half of next year and the prospect of commercializing the world’s first NK/T cell therapy.
뉴스픽의 주요 문장 추출 기술을 사용하여 “이데일리” 기사 내용을 3줄로 요약한 결과입니다. 일부 누락된 내용이 있어 전반적인 이해를 위해서는 본문 전체 읽기를 권장합니다.
